Skip to main content
PMC home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 1994 Jan 15;150(2):189–198.

Indications for treatment of Helicobacter pylori infection: a systematic overview.

S J Veldhuyzen van Zanten 1, P M Sherman 1
PMCID: PMC1486210  PMID: 8287341

Abstract

OBJECTIVE: To determine (a) the advantages and disadvantages of treatment options for the eradication of Helicobacter pylori and (b) whether eradication of H. pylori is indicated in patients with duodenal ulcer, nonucler dyspepsia and gastric cancer. DATA SOURCES: A MEDLINE search for articles published in English between January 1983 and December 1992 with the use of MeSH terms Helicobacter pylori (called Campylobacter pylori before 1990) and duodenal ulcer, gastric cancer, dyspepsia and clinical trial. Six journals and Current Contents were searched manually for pertinent articles published in that time frame. STUDY SELECTION: For duodenal ulcer the search was limited to studies involving adults, studies of H. pylori eradication and randomized clinical trials comparing anti-H. pylori therapy with conventional ulcer treatment. For nonulcer dyspepsia with H. pylori infection the search was limited to placebo-controlled randomized clinical trials. DATA EXTRACTION: The quality of each study was rated independently on a four-point scale by each author. For the studies of duodenal ulcer the outcome measures assessed were acute ulcer healing and time required for healing, H. pylori eradication and ulcer relapse. For the studies of nonulcer dyspepsia with H. pylori infection the authors assessed H. pylori eradication, the symptoms used as outcome measures and whether validated outcome measures had been used. DATA SYNTHESIS: Eight trials involving duodenal ulcer met our inclusion criteria: five were considered high quality, two were of reasonable quality, and one was weak. Six trials involving nonulcer dyspepsia met the criteria, but all were rated as weak. Among treatment options triple therapy with a bismuth compound, metronidazole and either amoxicillin or tetracycline achieved the highest eradication rates (73% to 94%). Results concerning treatment indications for duodenal ulcer were consistent among all of the studies: when anti-H. pylori therapy was added to conventional ulcer treatment acute ulcers healed more rapidly. Ulcer relapse rates were dramatically reduced after H. pylori eradication. All of the studies involving nonulcer dyspepsia assessed clearance rather than eradication of H. pylori. No study used validated outcome measures. A consistent decrease in symptom severity was no more prevalent in patients in whom the organism had been cleared than in those taking a placebo. Of the studies concerning gastric cancer none investigated the effect of eradication of H. pylori on subsequent risk of gastric cancer. CONCLUSIONS: There is sufficient evidence to support the use of anti-H. pylori therapy in patients with duodenal ulcers who have H. pylori infection, triple therapy achieving the best results. There is no current evidence to support such therapy for nonulcer dyspepsia in patients with H. pylori infection. Much more attention must be paid to the design of nonulcer dyspepsia studies. Also, studies are needed to determine whether H. pylori eradication in patients with gastritis will prevent gastric cancer.

Full text

PDF
189

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asaka M., Kimura T., Kudo M., Takeda H., Mitani S., Miyazaki T., Miki K., Graham D. Y. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992 Mar;102(3):760–766. doi: 10.1016/0016-5085(92)90156-s. [DOI] [PubMed] [Google Scholar]
  2. Barbara L., Camilleri M., Corinaldesi R., Crean G. P., Heading R. C., Johnson A. G., Malagelada J. R., Stanghellini V., Wienbeck M. Definition and investigation of dyspepsia. Consensus of an international ad hoc working party. Dig Dis Sci. 1989 Aug;34(8):1272–1276. doi: 10.1007/BF01537277. [DOI] [PubMed] [Google Scholar]
  3. Barthel J. S., Westblom T. U., Havey A. D., Gonzalez F., Everett E. D. Gastritis and Campylobacter pylori in healthy, asymptomatic volunteers. Arch Intern Med. 1988 May;148(5):1149–1151. [PubMed] [Google Scholar]
  4. Bayerdörffer E., Ottenjann R. The role of antibiotics in Campylobacter pylori associated peptic ulcer disease. Scand J Gastroenterol Suppl. 1988;142:93–100. [PubMed] [Google Scholar]
  5. Becx M. C., Janssen A. J., Clasener H. A., de Koning R. W. Metronidazole-resistant Helicobacter pylori. Lancet. 1990 Mar 3;335(8688):539–540. doi: 10.1016/0140-6736(90)90772-w. [DOI] [PubMed] [Google Scholar]
  6. Bell G. D. Anti-Helicobacter pylori therapy: clearance, elimination, or eradication? Lancet. 1991 Feb 2;337(8736):310–311. doi: 10.1016/0140-6736(91)90933-g. [DOI] [PubMed] [Google Scholar]
  7. Bernersen B., Johnsen R., Bostad L., Straume B., Sommer A. I., Burhol P. G. Is Helicobacter pylori the cause of dyspepsia? BMJ. 1992 May 16;304(6837):1276–1279. doi: 10.1136/bmj.304.6837.1276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Biasco G., Miglioli M., Barbara L., Corinaldesi R., di Febo G. Omeprazole, Helicobacter pylori, gastritis, and duodenal ulcer. Lancet. 1989 Dec 9;2(8676):1403–1403. doi: 10.1016/s0140-6736(89)92021-7. [DOI] [PubMed] [Google Scholar]
  9. Borody T. J., Cole P., Noonan S., Morgan A., Lenne J., Hyland L., Brandl S., Borody E. G., George L. L. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust. 1989 Oct 16;151(8):431–435. doi: 10.5694/j.1326-5377.1989.tb101251.x. [DOI] [PubMed] [Google Scholar]
  10. Borody T., Andrews P., Mancuso N., Jankiewicz E., Brandl S. Helicobacter pylori reinfection 4 years post-eradication. Lancet. 1992 May 23;339(8804):1295–1295. doi: 10.1016/0140-6736(92)91622-f. [DOI] [PubMed] [Google Scholar]
  11. Chiba N., Rao B. V., Rademaker J. W., Hunt R. H. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol. 1992 Dec;87(12):1716–1727. [PubMed] [Google Scholar]
  12. Coelho L. G., Passos M. C., Chausson Y., Costa E. L., Maia A. F., Brandao M. J., Rodrigues D. C., Castro L. P. Duodenal ulcer and eradication of Helicobacter pylori in a developing country. An 18-month follow-up study. Scand J Gastroenterol. 1992 May;27(5):362–366. doi: 10.3109/00365529209000088. [DOI] [PubMed] [Google Scholar]
  13. Coghlan J. G., Gilligan D., Humphries H., McKenna D., Dooley C., Sweeney E., Keane C., O'Morain C. Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study. Lancet. 1987 Nov 14;2(8568):1109–1111. doi: 10.1016/s0140-6736(87)91545-5. [DOI] [PubMed] [Google Scholar]
  14. Correa P., Yardley J. H. Grading and classification of chronic gastritis: one American response to the Sydney system. Gastroenterology. 1992 Jan;102(1):355–359. doi: 10.1016/0016-5085(92)91820-t. [DOI] [PubMed] [Google Scholar]
  15. Dooley C. P., Cohen H., Fitzgibbons P. L., Bauer M., Appleman M. D., Perez-Perez G. I., Blaser M. J. Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons. N Engl J Med. 1989 Dec 7;321(23):1562–1566. doi: 10.1056/NEJM198912073212302. [DOI] [PubMed] [Google Scholar]
  16. Dooley C. P., Cohen H. The clinical significance of Campylobacter pylori. Ann Intern Med. 1988 Jan;108(1):70–79. doi: 10.7326/0003-4819-108-1-70. [DOI] [PubMed] [Google Scholar]
  17. George L. L., Borody T. J., Andrews P., Devine M., Moore-Jones D., Walton M., Brandl S. Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust. 1990 Aug 6;153(3):145–149. doi: 10.5694/j.1326-5377.1990.tb136833.x. [DOI] [PubMed] [Google Scholar]
  18. Glupczynski Y., Burette A. Drug therapy for Helicobacter pylori infection: problems and pitfalls. Am J Gastroenterol. 1990 Dec;85(12):1545–1551. [PubMed] [Google Scholar]
  19. Glupczynski Y., Burette A., Labbe M., Deprez C., De Reuck M., Deltenre M. Campylobacter pylori-associated gastritis: a double-blind placebo-controlled trial with amoxycillin. Am J Gastroenterol. 1988 Apr;83(4):365–372. [PubMed] [Google Scholar]
  20. Goh K. L., Parasakthi N., Peh S. C., Wong N. W., Lo Y. L., Puthucheary S. D. Helicobacter pylori infection and non-ulcer dyspepsia: the effect of treatment with colloidal bismuth subcitrate. Scand J Gastroenterol. 1991 Nov;26(11):1123–1131. doi: 10.3109/00365529108998603. [DOI] [PubMed] [Google Scholar]
  21. Goodwin C. S., Blincow E. D., Warren J. R., Waters T. E., Sanderson C. R., Easton L. Evaluation of cultural techniques for isolating Campylobacter pyloridis from endoscopic biopsies of gastric mucosa. J Clin Pathol. 1985 Oct;38(10):1127–1131. doi: 10.1136/jcp.38.10.1127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Goodwin C. S., Marshall B. J., Blincow E. D., Wilson D. H., Blackbourn S., Phillips M. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol. 1988 Feb;41(2):207–210. doi: 10.1136/jcp.41.2.207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Graham D. Y., Börsch G. M. The who's and when's of therapy for Helicobacter pylori. Am J Gastroenterol. 1990 Dec;85(12):1552–1555. [PubMed] [Google Scholar]
  24. Graham D. Y., Klein P. D., Opekun A. R., Smith K. E., Polasani R. R., Evans D. J., Jr, Evans D. G., Alpert L. C., Michaletz P. A., Yoshimura H. H. In vivo susceptibility of Campylobacter pylori. Am J Gastroenterol. 1989 Mar;84(3):233–238. [PubMed] [Google Scholar]
  25. Graham D. Y., Lew G. M., Evans D. G., Evans D. J., Jr, Klein P. D. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. Ann Intern Med. 1991 Aug 15;115(4):266–269. doi: 10.7326/0003-4819-115-4-266. [DOI] [PubMed] [Google Scholar]
  26. Graham D. Y., Lew G. M., Klein P. D., Evans D. G., Evans D. J., Jr, Saeed Z. A., Malaty H. M. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992 May 1;116(9):705–708. doi: 10.7326/0003-4819-116-9-705. [DOI] [PubMed] [Google Scholar]
  27. Graham D. Y., Lew G. M., Malaty H. M., Evans D. G., Evans D. J., Jr, Klein P. D., Alpert L. C., Genta R. M. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992 Feb;102(2):493–496. doi: 10.1016/0016-5085(92)90095-g. [DOI] [PubMed] [Google Scholar]
  28. Graham D. Y., Lidsky M. D., Cox A. M., Evans D. J., Jr, Evans D. G., Alpert L., Klein P. D., Sessoms S. L., Michaletz P. A., Saeed Z. A. Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection. Gastroenterology. 1991 Jun;100(6):1653–1657. doi: 10.1016/0016-5085(91)90665-8. [DOI] [PubMed] [Google Scholar]
  29. Graham D. Y., Malaty H. M., Evans D. G., Evans D. J., Jr, Klein P. D., Adam E. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology. 1991 Jun;100(6):1495–1501. doi: 10.1016/0016-5085(91)90644-z. [DOI] [PubMed] [Google Scholar]
  30. Graham D. Y. Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med. 1993 Feb 4;328(5):349–350. doi: 10.1056/NEJM199302043280512. [DOI] [PubMed] [Google Scholar]
  31. Gregson D. B., Low D. E., Cohen M. M., Cooter N. B., Connon J. J., Wolman S. L., Simor A. E. The prevalence of Campylobacter pylori gastritis among asymptomatic adults. CMAJ. 1989 Jun 15;140(12):1449–1453. [PMC free article] [PubMed] [Google Scholar]
  32. Guyatt G. H., Veldhuyzen Van Zanten S. J., Feeny D. H., Patrick D. L. Measuring quality of life in clinical trials: a taxonomy and review. CMAJ. 1989 Jun 15;140(12):1441–1448. [PMC free article] [PubMed] [Google Scholar]
  33. Hentschel E., Brandstätter G., Dragosics B., Hirschl A. M., Nemec H., Schütze K., Taufer M., Wurzer H. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993 Feb 4;328(5):308–312. doi: 10.1056/NEJM199302043280503. [DOI] [PubMed] [Google Scholar]
  34. Hosking S. W., Ling T. K., Yung M. Y., Cheng A., Chung S. C., Leung J. W., Li A. K. Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. BMJ. 1992 Aug 29;305(6852):502–504. doi: 10.1136/bmj.305.6852.502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Hui W. M., Lam S. K., Ho J., Lai C. L., Lok A. S., Ng M. M., Lau W. Y., Branicki F. J. Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. Dig Dis Sci. 1991 May;36(5):577–582. doi: 10.1007/BF01297022. [DOI] [PubMed] [Google Scholar]
  36. Kang J. Y., Tay H. H., Wee A., Guan R., Math M. V., Yap I. Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study. Gut. 1990 Apr;31(4):476–480. doi: 10.1136/gut.31.4.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Lambert J. R., Dunn K., Borromeo M., Korman M. G., Hansky J. Campylobacter pylori--a role in non-ulcer dyspepsia? Scand J Gastroenterol Suppl. 1989;160:7–13. doi: 10.3109/00365528909091728. [DOI] [PubMed] [Google Scholar]
  38. Lanza F. L., Evans D. G., Graham D. Y. Effect of Helicobacter pylori infection on the severity of gastroduodenal mucosal injury after the acute administration of naproxen or aspirin to normal volunteers. Am J Gastroenterol. 1991 Jun;86(6):735–737. [PubMed] [Google Scholar]
  39. Loffeld R. J., Potters H. V., Stobberingh E., Flendrig J. A., van Spreeuwel J. P., Arends J. W. Campylobacter associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate. Gut. 1989 Sep;30(9):1206–1212. doi: 10.1136/gut.30.9.1206. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Logan R. P., Gummett P. A., Misiewicz J. J., Karim Q. N., Walker M. M., Baron J. H. One week eradication regimen for Helicobacter pylori. Lancet. 1991 Nov 16;338(8777):1249–1252. doi: 10.1016/0140-6736(91)92111-e. [DOI] [PubMed] [Google Scholar]
  41. Loo V. G., Sherman P., Matlow A. G. Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents. Antimicrob Agents Chemother. 1992 May;36(5):1133–1135. doi: 10.1128/aac.36.5.1133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Mainguet P., Delmée M., Debongnie J. C. Omeprazole, campylobacter pylori, and duodenal ulcer. Lancet. 1989 Aug 12;2(8659):389–390. doi: 10.1016/s0140-6736(89)90569-2. [DOI] [PubMed] [Google Scholar]
  43. Marshall B. J., Goodwin C. S., Warren J. R., Murray R., Blincow E. D., Blackbourn S. J., Phillips M., Waters T. E., Sanderson C. R. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet. 1988 Dec 24;2(8626-8627):1437–1442. doi: 10.1016/s0140-6736(88)90929-4. [DOI] [PubMed] [Google Scholar]
  44. Marshall B. J. The use of bismuth in gastroenterology. The ACG Committee on FDA-Related Matters. American College of Gastroenterology. Am J Gastroenterol. 1991 Jan;86(1):16–25. [PubMed] [Google Scholar]
  45. Morgan D., Kraft W., Bender M., Pearson A. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. The Gastrointestinal Physiology Working Group of Cayetano Heredia and The Johns Hopkins Universities. Gastroenterology. 1988 Nov;95(5):1178–1184. doi: 10.1016/0016-5085(88)90348-4. [DOI] [PubMed] [Google Scholar]
  46. Mégraud F., Brassens-Rabbé M. P., Denis F., Belbouri A., Hoa D. Q. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol. 1989 Aug;27(8):1870–1873. doi: 10.1128/jcm.27.8.1870-1873.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Nwokolo C. U., Lewin J. F., Hudson M., Pounder R. E. Transmucosal penetration of bismuth particles in the human stomach. Gastroenterology. 1992 Jan;102(1):163–167. doi: 10.1016/0016-5085(92)91796-7. [DOI] [PubMed] [Google Scholar]
  48. Patchett S., Beattie S., Leen E., Keane C., O'Morain C. Helicobacter pylori and duodenal ulcer recurrence. Am J Gastroenterol. 1992 Jan;87(1):24–27. [PubMed] [Google Scholar]
  49. Rauws E. A., Langenberg W., Houthoff H. J., Zanen H. C., Tytgat G. N. Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology. 1988 Jan;94(1):33–40. [PubMed] [Google Scholar]
  50. Rauws E. A., Tytgat G. N. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet. 1990 May 26;335(8700):1233–1235. doi: 10.1016/0140-6736(90)91301-p. [DOI] [PubMed] [Google Scholar]
  51. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis. 1992 Sep;11(9):777–781. [PubMed] [Google Scholar]
  52. Talley N. J., Phillips S. F. Non-ulcer dyspepsia: potential causes and pathophysiology. Ann Intern Med. 1988 Jun;108(6):865–879. doi: 10.7326/0003-4819-108-6-865. [DOI] [PubMed] [Google Scholar]
  53. Taylor D. N., Blaser M. J. The epidemiology of Helicobacter pylori infection. Epidemiol Rev. 1991;13:42–59. doi: 10.1093/oxfordjournals.epirev.a036078. [DOI] [PubMed] [Google Scholar]
  54. Veldhuyzen van Zanten S. J., Tytgat K. M., Jalali S., Goodacre R. L., Hunt R. H. Can gastritis symptoms be evaluated in clinical trials? An overview of treatment of gastritis, nonulcer dyspepsia and Campylobacter-associated gastritis. J Clin Gastroenterol. 1989 Oct;11(5):496–501. doi: 10.1097/00004836-198910000-00003. [DOI] [PubMed] [Google Scholar]
  55. Veldhuyzen van Zanten S. J., Tytgat K. M., Pollak P. T., Goldie J., Goodacre R. L., Riddell R. H., Hunt R. H. Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and Helicobacter pylori associated gastritis? J Clin Epidemiol. 1993 Mar;46(3):273–279. doi: 10.1016/0895-4356(93)90075-c. [DOI] [PubMed] [Google Scholar]
  56. Weil J., Bell G. D., Powell K., Morden A., Harrison G., Gant P. W., Jones P. H., Trowell J. E. Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication. Aliment Pharmacol Ther. 1991 Jun;5(3):309–313. doi: 10.1111/j.1365-2036.1991.tb00032.x. [DOI] [PubMed] [Google Scholar]
  57. de Magistris L. What is new on cancer research. Ital J Gastroenterol. 1991 Feb;23(2):107–108. [PubMed] [Google Scholar]
  58. van Zanten S. J., Goldie J., Hollingsworth J., Silletti C., Richardson H., Hunt R. H. Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. J Clin Pathol. 1992 Mar;45(3):225–227. doi: 10.1136/jcp.45.3.225. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES